Vaccinia Virus, Modified Encoding Ebola Virus Glycoprotein And Nucleoprotein
This recombinant modified vaccinia virus vector encodes Ebola virus glycoprotein and nucleoprotein antigens to elicit both humoral and cellular immune responses against Ebola virus disease. As a vaccine component, it uses the immunogenic vaccinia backbone to present Ebola-specific antigens to the immune system, generating protective antibodies and T-cell responses. This approach is part of multi-component Ebola vaccine strategies combining different vector platforms for prime-boost immunization.
Etki Mekanizması
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This recombinant modified vaccinia virus vector encodes Ebola virus glycoprotein and nucleoprotein antigens to elicit both humoral and cellular immune responses against Ebola virus disease. As a vaccine component, it uses the immunogenic vaccinia backbone to present Ebola-specific antigens to the immune system, generating protective antibodies and T-cell responses. This approach is part of multi-component Ebola vaccine strategies combining different vector platforms for prime-boost immunization.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Vaccinia Virus, Modified Encoding Ebola Virus Glycoprotein And Nucleoprotein is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068379. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vaccinia-virus-modified-encoding-ebola-virus-glycoprotein-and-nucleoprotein"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vaccinia-virus-modified-encoding-ebola-virus-glycoprotein-and-nucleoprotein/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vaccinia-virus-modified-encoding-ebola-virus-glycoprotein-and-nucleoprotein/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vaccinia-virus-modified-encoding-ebola-virus-glycoprotein-and-nucleoprotein/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vaccinia-virus-modified-encoding-ebola-virus-glycoprotein-and-nucleoprotein"></drugfyi-drug>